Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för evofosfamide. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

37 träffar

Bibliografisk träff 2016-09-01

Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models.

Stokes AM, Hart CP, Quarles CC.

Tomography · research-article; journal article · DOI 10.18383/j.tom.2016.00259

Bibliografisk träff 2016-08-17

A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.

Larue RT, Van De Voorde L, Berbée M, van Elmpt WJ, Dubois LJ, Panth KM, Peeters SG, Claessens A, Schreurs WM, Nap M, Warmerdam FA, Erdkamp FL, Sosef MN, Lambin P.

BMC Cancer · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1186/s12885-016-2709-z

Bibliografisk träff 2016-06-01

Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302.

Lohse I, Rasowski J, Cao P, Pintilie M, Do T, Tsao MS, Hill RP, Hedley DW.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.9654

Bibliografisk träff 2016-01-28

Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.

Sun JD, Liu Q, Ahluwalia D, Ferraro DJ, Wang Y, Jung D, Matteucci MD, Hart CP.

Cancer Biol Ther · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1080/15384047.2016.1139268

Bibliografisk träff 2016-01-09

Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models.

Liapis V, Zinonos I, Labrinidis A, Hay S, Ponomarev V, Panagopoulos V, Zysk A, DeNichilo M, Ingman W, Atkins GJ, Findlay DM, Zannettino AC, Evdokiou A.

Cancer Med · research support, non-u.s. gov't; research-article; journal article · DOI 10.1002/cam4.599

Bibliografisk träff 2015-10-01

[TH-302: a new hypoxia-activated cytostatic agent in pancreatic cancer treatment].

Schmalz C, Dunst J.

Strahlenther Onkol · comment; journal article · DOI 10.1007/s00066-015-0877-4

Bibliografisk träff 2010-06-07

Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.

Hu J, Handisides DR, Van Valckenborgh E, De Raeve H, Menu E, Vande Broek I, Liu Q, Sun JD, Van Camp B, Hart CP, Vanderkerken K.

Blood · research support, non-u.s. gov't; journal article · DOI 10.1182/blood-2010-02-269126